Informations générales (source: ClinicalTrials.gov)
Assessment and Follow-up of Patients With KRAS G12C-mutated Metastatic Non-Small Cell Lung Cancer Who Received Sotorasib as Part of the French Early Access Program (ATU) (LungKG12Ci)
Observational
Intergroupe Francophone de Cancerologie Thoracique (Voir sur ClinicalTrials)
mars 2022
décembre 2024
19 octobre 2024
The purpose of the IFCT2102 Lung KG12Ci study is to closely monitor cohort ATU
applications in order to collect retrospectively, as soon as possible after inclusion and
under real-life conditions, the efficacy data on sotorasib (AMG 510) as well as the
demographic and molecular characteristics of patients.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Gaelle ROUSSEAU | 29/03/2024 01:30:14 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Cochin | Contact (sur clinicalTrials) | ||||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Rouen - CHU - Rouen - France | Contact (sur clinicalTrials) | ||||
| Strasbourg - CHU - Strasbourg - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
- Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib
- Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co
mutations allowed)
- Patients who received at least one dose of the treatment with sotorasib as part of
the French Early Access Program (ATU program)
- Patients who were informed about the study and do not object for their data to be
collected
- Age > 18 years
- Patients with Stage IV NSCLC at time of initiation of treatment with sotorasib
- Presence of KRAS G12C mutation diagnosed on tumor sample and/or on liquid biopsy (co
mutations allowed)
- Patients who received at least one dose of the treatment with sotorasib as part of
the French Early Access Program (ATU program)
- Patients who were informed about the study and do not object for their data to be
collected
- Age > 18 years
- Patients enrolled in a sotorasib clinical trial
- Patients with a psychiatric history that hinders the comprehension of the
information leaflet
- Patients under curatorship or guardianship
- Unable to obtain data collection